Teplizumab treatment addresses underlying cause of Type 1

Shares of Precigen have increased after the company’s Phase 1b/2a study of its AG019 ActoBiotics, designed to address the underlying cause of Type 1 diabetes. The treatment was studied in Phase 1b as a monotherapy for adults aged 18–42 and adolescents aged 12–17. In Phase 2a, it was used as a combination therapy with teplizumab.

“We are encouraged by the Phase 1b/2a primary analysis results and the implications for the potential of AG019 as an easy-to-take oral monotherapy or combination therapy with teplizumab,” Pieter Rottiers, chief executive of Precigen’s ActoBio division, said in a statement. He added that the results, “suggest the ability of AG019 to modulate a patient’s immune system in a precise, antigen-specific manner to address the underlying cause of Type 1 diabetes.”


Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags